Can Strattera Cause Bloody Nose?
No, atomoxetine (Strattera) does not commonly cause epistaxis (nosebleeds), and there is no established causal relationship between this medication and nosebleeds based on available evidence.
Evidence from FDA Drug Label
The FDA prescribing information for Strattera does not list epistaxis as a recognized adverse effect 1. The documented side effects include:
- Sympathetic nervous system activation: tachycardia, blood pressure elevation, mydriasis, dry mouth
- Common adverse events: gastrointestinal symptoms, somnolence, dizziness, tremor
- Postmarketing reports: anxiety (but not epistaxis)
A comprehensive safety review of atomoxetine covering over a decade of research in children and adolescents examined seven major safety topics—suicidality, aggression/hostility, psychosis/mania, seizures, hepatic effects, cardiovascular effects, and growth/development—but epistaxis was not identified as a safety concern 2.
Clinical Context
The epistaxis guidelines extensively discuss risk factors for nosebleeds, including 3, 4:
- Anticoagulant medications (warfarin, DOACs, heparin)
- Antiplatelet agents (aspirin, clopidogrel)
- Hypertension (though causal relationship unclear)
- Inherited bleeding disorders (von Willebrand disease, hemophilia)
- Hereditary hemorrhagic telangiectasia
Atomoxetine is not mentioned among medications associated with epistaxis risk in these comprehensive guidelines.
Practical Recommendation
If a patient on Strattera develops nosebleeds:
- Do not attribute it to atomoxetine without investigating other causes
- Evaluate for common epistaxis risk factors: digital trauma (especially in children), nasal dryness, environmental factors, concurrent anticoagulant use, hypertension, or bleeding disorders
- Consider that 60% of the general population experiences at least one nosebleed, with 3 out of 4 children having at least one episode 3
- Manage the epistaxis using standard first-line treatments: direct nasal compression, topical vasoconstrictors, cautery, or packing as indicated 3
The temporal association between starting Strattera and developing epistaxis is likely coincidental rather than causal, particularly given the high baseline prevalence of nosebleeds in the general population and the absence of this adverse effect in extensive safety monitoring.